Lakefront Biotherapeutics is a brand-new company record, and its full research profile isn't ready yet.
lakefrontbio.comCrawled Oct 26, 2026
The page explains Lakefront’s clinical research approach, informed consent, and resources for locating studies in U.S. and European trial registries.
T cell-engagers (TCEs) are bispecific antibodies that simultaneously target CD3 on T cells and specific antigens on the cell surface to enable T cell-mediated depletion of the target cell.
The page describes Lakefront’s immunology pipeline, led by gamgertamig (OM336), a BCMAxCD3 T-cell engager in development for autoimmune diseases.
The page lists scientific papers, abstracts, and posters on gamgertamig, BCMA-directed T-cell engagers, B-cell depletion, and immune reset research.
The page lists past and future webinars offering insights about Lakefront Biotherapeutics for investors and analysts, along with investor event participation.
Galapagos NV will participate in the 41st Annual J.P. Morgan Healthcare Conference in January 2023.
The company’s Board of Directors provides strategic guidance, oversees governance, manages risks, accesses resources, and ensures accountability to shareholders.
Pairing rigorous analysis with a drive to action, Lakefront Biotherapeutics’s Leadership Team drives innovation to bring meaningful medicines to patients around the world.
Lakefront Biotherapeutics is a clinical-stage immunology and inflammation company developing a pipeline centered on gamgertamig.
The page covers Lakefront’s strategic partnerships, its relationship with Gilead Sciences, the Ouro Medicines transaction, and business development opportunities.
The page provides contact information for Lakefront Biotherapeutics’ corporate headquarters in Mechelen, Belgium.
The page lists Lakefront Biotherapeutics’ locations in Belgium, Netherlands, United States, Switzerland, France, Austria, Germany, Italy, Nordics, Spain, UK, and Ireland.
Lakefront Biotherapeutics is a clinical-stage biotech advancing immunology and inflammation programs, anchored by gamgertamig for autoimmune diseases.
The company has established guidelines to ensure communications align with its mission and ethical, legal, and regulatory standards.